Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron

Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats

Fundacio Privada Institut D'investigacio Oncologica De Vall D'hebron

Fundacio Privada Institucio Catalana De Recera I Estudis Avancats

Fundació Privada Institut De Recerca Hospital Universitari Vall Hebron

Joaquin Arribas Lopez

Kim Pedersen

Pier-Davide Angellini

Josep Lluis Parra Palau

Josep Liuis Parra Palau

Sirle Laos

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

Antibodies against HER2 truncated variant CTF-611

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

Method for diagnosing cancers expressing the HER2 receptor or its truncated variants

Growing community of inventors

Cerdanyola del Valles, Spain

Joaquin Arribas Lopez